2025 Guidelines for the Evaluation and Management of Adults With Congenital Heart Disease
December 19, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
darizmetinib
Class :
Mitogen-activated protein 2 kinase inhibitor
Brand Name :
N/A
Synonyms :
darizmetinib
Class :
Mitogen-activated protein 2 kinase inhibitor
Dosage Forms & Strengths
It is under investigation for NASH and hepatocellular carcinoma. As it is still under clinical trials, its safety and effectiveness are not determined
It is studied for its potential to treat liver diseases such as non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC)
It is still in the early stages of clinical trials and its efficacy and safety are yet to be established
Not determined
Refer to adult dosing
Actions and Spectrum
Darizmetinib, a MAP2K inhibitor, is employed to treat cancer. MAP4K is an essential regulator of liver regeneration.
Frequency not defined
None
Black Box Warning
There is no black box warning
Contraindication/Caution:
There are no specific contraindications
Pregnancy/Lactation
Pregnancy consideration:
Pregnancy category: Not assigned
Lactation: Excretion into human milk is unknown
Pregnancy Categories:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments
Category C: There was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: Adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
Not known
Pharmacodynamics
There is no sufficient data available.
Pharmacokinetics
Limited information available on ADME.
Administration
Darizmetinib is under clinical trials hence the administration is not known.
Patient information leaflet
Generic Name: darizmetinib
Why do we use darizmetinib?
Darizmetinib is being investigated for the treatment of liver diseases like NASH and HCC, showing potential to boost liver regeneration and decrease hepatocyte death.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
